BK-6-MAPB

BK-6-MAPB
Clinical data
Other names	BK-6-MAPB; NM-PrBF6; 6-[2-(Methylamino)propanoyl]benzofuran
Drug class	Entactogen; Serotonin releasing agent
ATC code	None;
Identifiers
	IUPAC name 1-(1-benzofuran-6-yl)-2-(methylamino)propan-1-one;
PubChem CID	163982955;
ChemSpider	129893181;
ChEMBL	ChEMBL5397645;
Chemical and physical data
Formula	C12H13NO2
Molar mass	203.241 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC(C(=O)c1ccc2c(c1)occ2)C;
	InChI InChI=1S/C12H13NO2/c1-8(13-2)12(14)10-4-3-9-5-6-15-11(9)7-10/h3-8,13H,1-2H3; Key:SZYQYVVTRVJIPK-UHFFFAOYSA-N;

βk-6-MAPB, or BK-6-MAPB, also known as NM-PrBF6 or as 6-[2-(methylamino)propanoyl]benzofuran, is a putative entactogen of the benzofuran and cathinone groups.^[1]^[2] It was patented by Matthew Baggott and Tactogen.^[1]^[3]^[4] The drug is known to act as a potent serotonin releasing agent.^[1] βk-6-MAPB was encountered as a novel designer drug online in 2019.^[2]

References

^ ^a ^b ^c WO 2021/252538, Baggott M, "Advantageous benzofuran compositions for mental disorders or enhancement", published 16 December 2021, assigned to Tactogen Inc.
^ ^a ^b "bk-MAPB". AIPSIN Monitoring. 25 June 2019.
^ WO 2023/107653, Baggott MJ, Lofthus SJ, De Leona XM, Singh A, Hudgins CJ, "Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement", published 21 September 2023, assigned to Tactogen Inc.
^ WO 2023/107715, Baggott M, Dalziel S, "Specialized combinations for mental disorders or mental enhancement", published 15 June 2023, assigned to Tactogen Inc.